CoChat

DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice

Open access
Han, Zongchao, Conley, Shannon M., Makkia, Rasha S., Cooper, Mark J., Naash, Muna I. · 2012 · Journal of Clinical Investigation

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Mutations in the photoreceptor-specific flippase ABCA4 are associated with Stargardt disease and many other forms of retinal degeneration that currently lack curative therapies. Gene replacement is a logical strategy for ABCA4-associated disease, particularly given the current success of traditional viral-mediated gene delivery, such as with adeno-associated viral (AAV) vectors. However, the large size of the ABCA4 cDNA (6.8 kbp) has hampered progress in the development of genetic treatments. Nonviral DNA nanoparticles (NPs) can accommodate large genes, unlike traditional viral vectors, which have capacity limitations. We utilized an optimized DNA NP technology to subretinally deliver ABCA4 to Abca4-deficient mice. We detected persistent ABCA4 transgene expression for up to 8 months after injection and found marked correction of functional and structural Stargardt phenotypes, such as improved recovery of dark adaptation and reduced lipofuscin granules. These data suggest that DNA NPs may be an excellent, clinically relevant gene delivery approach for genes too large for traditional viral vectors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci64833

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Glushakova, 2006, Mol Vis., 12, 298

Cited by

See all 150

Metadata

Authors
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I.
Affiliations
  • University of Oklahoma Health Sciences Center (US)
  • University of Oklahoma (US)
  • Copernicus Therapeutics (United States) (US)
Corresponding author
Naash, Muna I.
Venue
Journal of Clinical Investigation
Published
2012-09-04
Volume
122
Issue
9
Pages
3221-3226
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2055017226
Cited by
150
References
19
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 5 · 2021: 21 · 2020: 11 · 2019: 9 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 18 · 2014: 15 · 2013: 15 · 2012: 1
FWCI
6.29
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Foundation Fighting Blindness
  • University of Oklahoma
  • National Institutes of Health
  • University of Oklahoma Health Sciences Center
  • National Eye Institute (R01EY018656, R01EY022778, R01EY010609)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
DNA nanoparticles, ABCA4, Stargardt disease, gene replacement therapy, non-viral gene delivery, subretinal injection, retinal degeneration, photoreceptors, lipofuscin granules, dark adaptation
MeSH terms
Analysis of Variance, Animals, Corneal Dystrophies, Hereditary, DNA, Humans, Lipofuscin, Mice, Inbred C57BL, Phenotype, Genetic Therapy, Gene Expression, Mice, Knockout, ATP-Binding Cassette Transporters, Transgenes, Mice, Nanoparticles, Retinal Pigment Epithelium, Injections, Intraocular

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.